Chi-Med's Phase III cancer trial of fruquintinib meets primary endpoint

Biopharmaceutical company Hutchison China MediTech (Chi-Med) has reported top-line results from its Phase III pivotal registration trial (FRESCO) of fruquintinib (HMPL-013) in 416 patients with locally advanced or metastatic colorectal cancer (CRC) i …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news